Candel Therapeutics, Inc. (CADL): Nasdaq/NYSE listing notice — Candel Therapeutics receives Nasdaq delisting notice for bid price below $1.00

Candel Therapeutics, Inc.

Nasdaq notified CADL that bid price below $1.00 for 30 consecutive business days.
Company has 180 days, until May 13, 2024, to regain compliance.
Compliance requires closing bid price at $1.00 or more for 10 consecutive business days.
If not compliant, may qualify for second 180-day period by transferring to Nasdaq Capital Market.
Common stock continues trading on Nasdaq Global Market under CADL; no immediate effect.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Candel Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

November 15, 2023, Candel Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.01 per share (the “Common Stock”), had been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notice has no effect at this time on the Common Stock, w

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-065567

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.